Latest News about MNMD
Recent news which mentions MNMD
FDA Greenlight Sets the Stage for Upside With Mind Medicine
February 08, 2022
Tickers
MNMD
From InvestorPlace
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
February 07, 2022
From Benzinga
Small Pharma, Mind Medicine Among Top Psychedelic Movers Of Today
February 04, 2022
From Benzinga
From Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
February 02, 2022
From Benzinga
New Psychedelics ETF Launches On NYSE Arca
February 02, 2022
From Benzinga
Mindset Pharma, Allied Among Top Psychedelic Movers Of Today
February 01, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From January 28, 2022
January 28, 2022
From Benzinga
From Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
From Benzinga
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 26, 2022
From Benzinga
MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years
January 26, 2022
Tickers
MNMD
From Benzinga
51 Biggest Movers From Yesterday
January 26, 2022
From Benzinga
Mind Medicine, Mindset Pharma Among Top Psychedelic Movers Of Today
January 25, 2022
From Benzinga
From InvestorPlace
From InvestorPlace
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jan. 25, 2022: MSFT, SHOP, ERIC, MNMD, TSLA
January 25, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
From Benzinga
Psyched: Eleusis To Go Public Via Merger, New Psychedelics Bills In Utah, Virginia, Kansas And Missouri
January 24, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From January 17, 2022
January 17, 2022
From Benzinga
From Benzinga
Psyched: Canada's Access To Psychedelic Medicines, Psilocybin No Cognitive Side Effects, Psilocybin Bill Washington
January 10, 2022
From Benzinga
MindMed Completes Phase 1 Clinical Trial Of Non-Hallucinogenic Proprietary Derivative Of Ibogaine
January 04, 2022
Tickers
MNMD
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.